Pain
People spend much of their lives trying to soothe physical pain. Tragically, the overconsumption of pain-management opioid drugs continues to shatter lives owing to their addictive nature. But a new era of pain science and therapy could be dawning, including a heightened recognition of the power of non-pharmaceutical, non-invasive methods of easing the hurt that is universal to the human condition.
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from Pacira BioSciences, Inc. in producing this Outlook. The sponsor retains sole responsibility for the following message.
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
